Yuhan Corp announced on Tuesday that the results of the Phase 1a clinical trial of its allergy drug candidate YH35324 were published in the SCI-ranked International Journal of Immunopharmacology.

YH35324 is a novel anti-immunoglobulin E (Anti-IgE) class Fc fusion protein drug. Its main mechanism of action improves allergy symptoms by reducing the level of free IgE in the blood.

The Phase 1a clinical trial was the first time YH35324 was administered to humans (First-In-Human (FIH)). The study was conducted from September 2021 to January 2023 in allergy medicine departments of 4 Korean university hospitals and included a total of 68 patients.

The study was conducted in two